Britain and America have signed a important bilateral deal that will maintain no levies on UK pharmaceutical exports entering the American market.
Agreement Details of the Deal
Under the terms of the agreement, the UK has committed to increase spending on pharmaceuticals through the NHS. This commitment ensures that duties on these key exports will stay at zero for a duration of 36 months.
This agreement is in response to previous statements to hike duties on patented pharmaceutical products, with increases discussed up to one hundred percent.
"This arrangement with the United Kingdom reinforces the global environment for new treatments and introduces much-needed fairness to transatlantic pharmaceutical trade," a statement declared.
Economic Impact
Drugs represent one of the UK's biggest goods shipped to the US, which is easily the biggest destination for large companies like GSK and AstraZeneca.
Trade data indicate that in the one-year period to the end of September, the UK sold medicines valued at over eleven billion pounds to the US. This amount represented 17.4% of British export trade in that span.
"This deal safeguards work, increases funding and facilitates the UK to emerge as a global hub for medical research," a government official stated.
Specific NHS Changes
The agreement entails several key changes from the British government:
- Revised Affordability Limit: The UK will lift the affordability limit at which it deems new medicines to be unaffordable by 25%.
- Higher Drug Budget: There is a goal to increase overall health service expenditure on drugs from 0.3% of the national economy to 0.6 percent over the next decade.
- Refund Ceiling: The amount pharmaceutical firms must return to the NHS to control costs will be restricted at fifteen percent. Last year, refunds were more than 20%.
Industry Background
The deal follows a ongoing tension between the sector and the ministers over drug pricing and NHS adoption.
These tensions were exacerbated by assertions that US consumers were paying significantly more for the same drugs than people in the UK and Europe.
Over the last 18 months, several large manufacturing plans in the UK have been halted or cancelled, while substantial funding commitments have been announced toward American operations.
A senior figure publicly accepted that the NHS must invest a greater share on medicines, noting that its budget allocation on drugs had declined as a percentage of its resources over the last ten years.
